The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Where will trispecific antibodies fit into the lymphoma treatment landscape?
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of trispecific antibodies in the treatment landscape for lymphoma. He suggests that while they have great potential, they face a complex landscape with many agents already available, meaning their initial impact may be limited to patients who have already received prior CAR T-cell or bispecific antibody treatments. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Trispecific antibodies have great potential, but the landscape has gotten incredibly complex the past few years. We already have multiple bispecific antibodies targeting CD20, now targeting CD19. There are a few others that are coming that are targeting different B-cell antigens. And so trispecifics are not coming into a field where it’s wide open and they don’t have to kind of fit into somebody else’s wake...
Trispecific antibodies have great potential, but the landscape has gotten incredibly complex the past few years. We already have multiple bispecific antibodies targeting CD20, now targeting CD19. There are a few others that are coming that are targeting different B-cell antigens. And so trispecifics are not coming into a field where it’s wide open and they don’t have to kind of fit into somebody else’s wake. They have to find a way to fit into the algorithm that’s already gotten quite complicated. So trispecifics may be advantageous, but are they advantageous enough that makes up for the complicated landscape? Still to be determined. And I think what’s likely to happen, at least initially in trials for bispecifics, is that patients will have been treated with, I’m sorry, for trispecifics. What’s initially likely to happen is that they will have to be in patients who’ve already had a prior CAR T-cell or a prior bispecific antibody. And it may be difficult to treat patients who are naive to either CAR or bispecific on studies with trispecifics, just because those are more mature and have more of a track record. So trispecifics have a steeper hill to climb just because they’re coming late to the game.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
